Jiahong B. Chen

Huizhou, 516001, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

The pseudouridine epitranscriptomic landscape of advanced prostate cancer therapeutic resistance identifies TIMM17A as a key player.

The pseudouridine epitranscriptomic landscape of advanced prostate cancer therapeutic resistance identifies TIMM17A as a key player.

Journal: Translational oncology

Published: May 25, 2026

Exploring DNA topoisomerase II alpha in adrenocortical carcinoma through multi-omics analysis: a potential biomarker and therapeutic target.

Exploring DNA topoisomerase II alpha in adrenocortical carcinoma through multi-omics analysis: a potential biomarker and therapeutic target.

Journal: Acta biochimica et biophysica Sinica

Published: August 28, 2025

Rare Cancer Explorer 1.0 (RaCE 1.0): a dedicated database and analytical platform focused on rare cancers.

Rare Cancer Explorer 1.0 (RaCE 1.0): a dedicated database and analytical platform focused on rare cancers.

Journal: Nucleic acids research

Published: June 26, 2025

Integrated multi-omics and experimental approaches identify fascin actin-bundling protein 1 as an unfavorable prognostic biomarker in adrenocortical carcinoma.

Integrated multi-omics and experimental approaches identify fascin actin-bundling protein 1 as an unfavorable prognostic biomarker in adrenocortical carcinoma.

Journal: Acta biochimica et biophysica Sinica

Published: May 19, 2025

Cell division cycle 20 promotes tumor progression and predicts poor clinical outcome in childhood and adult adrenocortical carcinoma.

Cell division cycle 20 promotes tumor progression and predicts poor clinical outcome in childhood and adult adrenocortical carcinoma.

Journal: Journal of clinical & translational endocrinology

Published: March 27, 2025

Multi-omics profiling highlights karyopherin subunit alpha 2 as a promising biomarker for prognosis and immunotherapy respond in pediatric and adult adrenocortical carcinoma.

Multi-omics profiling highlights karyopherin subunit alpha 2 as a promising biomarker for prognosis and immunotherapy respond in pediatric and adult adrenocortical carcinoma.

Journal: Annals of medicine

Published: December 03, 2024

Unveiling SMAD family member 6 as a novel biomarker for prognosis and immunotherapy response in testicular germ cell tumors.

Unveiling SMAD family member 6 as a novel biomarker for prognosis and immunotherapy response in testicular germ cell tumors.

Journal: Andrology

Published: November 14, 2024

Phosphoribosyl transferase domain containing 1: A prognostic biomarker in testicular germ cell tumors.

Phosphoribosyl transferase domain containing 1: A prognostic biomarker in testicular germ cell tumors.

Journal: Molecular therapy. Oncology

Published: August 19, 2024

Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway.

Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway.

Journal: Journal of translational medicine

Published: September 07, 2023

Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma.

Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma.

Journal: Endocrine-related cancer

Published: June 13, 2023

N6-methyladenosine modified lncRNAs signature for stratification of biochemical recurrence in prostate cancer.

N6-methyladenosine modified lncRNAs signature for stratification of biochemical recurrence in prostate cancer.

Journal: Human genetics

Published: May 26, 2023

Integrated high-throughput analysis identifies super enhancers in metastatic castration-resistant prostate cancer.

Integrated high-throughput analysis identifies super enhancers in metastatic castration-resistant prostate cancer.

Journal: Frontiers in pharmacology

Published: March 21, 2023

Showing 1-12 of 20

Last Updated: 09/26/2026